Acute cardiac care & resuscitation

Lower noradrenaline-mediated mean arterial pressure target in patients with acute myocardial infarction-related cardiogenic shock: rationale and design of the NORshock study

EuroInterventionPublished international, open-label, multicentre, randomised superiority trial

Study context

Population
Patients with acute myocardial infarction-related cardiogenic shock (AMI-CS)patients to be allocated (planned)
Participants
776 patients
Planned comparison
a lower noradrenaline-mediated mean arterial pressure (MAP)-target regimen (MAP of 55 mmHg) compared with a standard noradrenaline-mediated MAP-target regimen (MAP of at least 65 mmHg)
Methodological details1:1 allocation
  • 1:1 allocation

No results yet. This paper sets out the design of a trial; its results are to come.

Further findings

Study design (no results reported) · within 30 days

Hypothesis: permissive hypotension strategy superior to standard care for combined endpoint of all-cause death and renal replacement therapy
  • Rationale and design paper

Original publication

Lower noradrenaline-mediated mean arterial pressure target in patients with acute myocardial infarction-related cardiogenic shock: rationale and design of the NORshock study. EuroIntervention. Published 7 September 2026. doi:10.4244/eij-d-26-00112

Summarised from the published abstract; every number is checked against it

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.